Leucovorin® (Pfizer) – Calcium Folinate

Calcium Folinate in Autism - How It May Help Your Children

When a child is diagnosed with autism, many parents ask the same question: Are there any ways to specifically support my child’s development?

 

One treatment that has gained increasing scientific attention in recent years is Calcium Folinate (Leucovorin®). Although calcium folinate is not a cure for autism, research suggests that it may improve important areas such as language, attention, and social interaction in a subgroup of children with autism.

Leucovorin® is a registered trademark of Pfizer Inc. The name Leucovorin® is used in reference to the active substance contained in our Calcium Folinate product.

What Improvements Have Been Reported

What Is Calcium Folinate?

Calcium Folinate is an active form of folate (vitamin B9). Folate is essential for numerous processes in the brain, including the development of nerve cells, communication between neurons, and the production of important neurotransmitters such as serotonin and dopamine.

 

Adequate folate availability is particularly important during early brain development.

How Does Calcium Folinate Work?

Calcium folinate can partially use alternative transport pathways to enter the brain. By doing so, it may bypass the blocked transport system and provide the brain with a greater supply of biologically available folate. 

 

The goal is not to cure autism, but rather to improve the conditions necessary for optimal brain function.

Why Does Folate Matter in Autism?

Some children with autism do not have a deficiency of folate in their blood. Instead, the problem is that insufficient folate reaches the brain.

 

One possible explanation is the presence of folate receptor alpha autoantibodies (FRAAs). These antibodies interfere with the transport mechanism that normally carries folate across the blood-brain barrier.

 

A simple way to understand this is to imagine a locked door:

  • There is enough folate in the bloodstream.
  • However, the “key” that opens the door does not work properly.
  • As a result, the brain receives less folate than it actually needs.

 

This condition is known as Folate Receptor Alpha Deficiency (FRαD) or cerebral folate deficiency caused by folate receptor autoantibodies.

Should Testing Be Performed Before Treatment?

Ideally, yes! A blood test can detect folate receptor alpha autoantibodies (FRAAs).

 

If the test is positive, the likelihood of responding to calcium folinate therapy is generally higher.

 

However, a positive test does not guarantee that a child will benefit, and a negative test does not necessarily mean that calcium folinate will be ineffective.

Frequently Asked Questions

Yes! More recent studies and clinical experience suggest that some children without detectable folate receptor autoantibodies may also benefit from calcium folinate therapy.

 

Several explanations have been proposed:

 

  • Current testing may not identify all disturbances of folate metabolism.
  • Genetic variations affecting folate metabolism may play a role.
  • Alternative folate transport mechanisms within the brain may be impaired.
  • Some children may have functional metabolic abnormalities that are not yet fully understood.

 

For this reason, experienced physicians may recommend a carefully monitored therapeutic trial of calcium folinate even in children with a negative FRAA test, after discussing the potential benefits and limitations with the family.

Calcium folinate has been used safely in medicine for several decades and is generally considered to be well tolerated.

 

Occasionally, the following side effects may occur:

 

  • Temporary restlessness
  • Increased activity or hyperactivity
  • Sleep disturbances
  • Irritability
  • Rarely, mild gastrointestinal discomfort

 

These side effects are usually mild and often improve after adjusting the dosage.

Some families notice early improvements within a few weeks.

 

For others, it may take two to four months before meaningful changes become apparent.

 

Since brain development occurs gradually, treatment is often continued for several months and regularly monitored by the treating physician.

Several randomized controlled studies have demonstrated that calcium folinate can improve language and communication, particularly in children with folate receptor alpha autoantibodies.

 

Although the current evidence is encouraging, additional large-scale studies are needed to determine which children benefit the most and what treatment duration is optimal.

Our Conclusions

Calcium folinate is not a cure for autism. However, it represents a scientifically supported adjunctive treatment that may improve brain function and facilitate developmental progress in a subset of children with autism.

 

A positive FRAA test increases the likelihood of a favorable response, but a carefully supervised therapeutic trial may also be considered in selected children with a negative test result.

our garantee

Expert Care Built on Years of Excellence

As part of our comprehensive treatment approach, STEM Cell Vienna offers an individualized calcium folinate therapy tailored to your child’s specific needs. Our goal is to support neurological development as effectively as possible and help every child reach their fullest potential.

 

Each treatment plan is carefully designed and continuously adapted to meet the individual needs of your child under medical supervision.

Fill out the Form

Discover the unique advantages of STEM Cell Treatment for your long-term health. Take a moment to complete the form with care, ensuring every required field is filled in so we can offer the most accurate guidance.

MAIN MENU

Transparency and Non-Promotional Position

The Pro Bono Program Is Not a Marketing Instrument

The medical and administrative teams expressly dissociate themselves from any form of advertising or promotional activity in relation to the Pro Bono Program, whether the support provided is partial or full.

Respect for patient dignity, privacy, and confidentiality remains a fundamental priority. Accordingly, no personal data, identifying information, or photographs of patients or of the parents of children with medical conditions will be published.

Clarification Regarding Published Materials

Context of Video and Graphic Content

Any video or graphic materials displayed on this platform include only patients or families who:

  • Have not benefited from the Pro Bono Program;

  • Have benefited partially or fully from the Program, in collaboration with associations, sponsors, or through direct support provided by STEM Cell Vienna

This clarification is provided in the interest of transparency and to ensure a clear understanding of the context in which such materials were produced and published.